Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Bayer, Onyx Submit sNDA for Nexavar | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Bayer, Onyx Submit sNDA for Nexavar

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. have submitted a sNDA to the FDA for Nexavar for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer. Nexavar is currently approved for the treatment of advanced kidney cancer. The companies are also planning a Phase III study of Nexavar in the adjuvant treatment of HCC following the complete removal of early stage liver cancer.

The sNDA is based on positive data from the international, Phase III, placebo-controlled Sorafenib HCC Assessment Randomized Protocol (SHARP) trial, which demonstrated that Nexavar extended overall survival by 44% in patients with HCC versus placebo. There were no significant differences in serious adverse event rates between the Nexavar and placebo-treated groups. Currently, there are no FDA-approved drug therapies that significantly extend survival of patients with liver cancer.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters